SI2338487T1 - Kombinacijska terapija z inhibitorji PARP - Google Patents
Kombinacijska terapija z inhibitorji PARPInfo
- Publication number
- SI2338487T1 SI2338487T1 SI200731329T SI200731329T SI2338487T1 SI 2338487 T1 SI2338487 T1 SI 2338487T1 SI 200731329 T SI200731329 T SI 200731329T SI 200731329 T SI200731329 T SI 200731329T SI 2338487 T1 SI2338487 T1 SI 2338487T1
- Authority
- SI
- Slovenia
- Prior art keywords
- combination therapy
- parp inhibitors
- parp
- inhibitors
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75944506P | 2006-01-17 | 2006-01-17 | |
US80411206P | 2006-06-07 | 2006-06-07 | |
US85004206P | 2006-10-06 | 2006-10-06 | |
US82926106P | 2006-10-12 | 2006-10-12 | |
US86751806P | 2006-11-28 | 2006-11-28 | |
EP11157696.3A EP2338487B1 (en) | 2006-01-17 | 2007-01-17 | Combination therapy with PARP inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2338487T1 true SI2338487T1 (sl) | 2014-01-31 |
Family
ID=38141258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731329T SI2338487T1 (sl) | 2006-01-17 | 2007-01-17 | Kombinacijska terapija z inhibitorji PARP |
Country Status (14)
Country | Link |
---|---|
US (4) | US20070265324A1 (sl) |
EP (3) | EP2338487B1 (sl) |
JP (4) | JP5289060B2 (sl) |
CN (1) | CN101370497B (sl) |
CA (1) | CA2635691C (sl) |
DK (1) | DK2338487T3 (sl) |
ES (1) | ES2437132T3 (sl) |
HR (1) | HRP20131180T1 (sl) |
ME (1) | ME02121B (sl) |
PL (1) | PL2338487T3 (sl) |
PT (1) | PT2338487E (sl) |
RS (1) | RS53082B (sl) |
SI (1) | SI2338487T1 (sl) |
WO (1) | WO2007084532A2 (sl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200312A3 (en) | 1998-11-03 | 2002-12-28 | Basf Ag | Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use |
US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
EP1957477B1 (en) * | 2005-09-29 | 2011-12-07 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
CN101511821B (zh) * | 2006-05-02 | 2013-07-17 | Abbvie公司 | 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂 |
WO2008030891A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
EP2217227B1 (en) * | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
RU2010136966A (ru) * | 2008-02-04 | 2012-03-20 | Байпар Сайенсиз, Инк. (Us) | Способы диагностики и лечения заболеваний, опосредованных parp |
CN103052390A (zh) * | 2010-08-03 | 2013-04-17 | 内尔维阿诺医学科学有限公司 | 包含parp-1抑制剂和抗肿瘤剂的治疗组合 |
TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
CN103687597A (zh) | 2011-04-11 | 2014-03-26 | 艾伯维公司 | 用于治疗cipn的parp抑制剂 |
JP2015521188A (ja) | 2012-05-15 | 2015-07-27 | アッヴィ・インコーポレイテッド | 脳転移を処置するための全脳放射線療法と併用するベリパリブ |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
CN104230896A (zh) * | 2013-06-17 | 2014-12-24 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
TW201600086A (zh) | 2013-12-10 | 2016-01-01 | 艾伯維有限公司 | 用於治療三陰性乳癌之維利帕尼(veliparib)與卡鉑之組合 |
CA2934552C (en) * | 2014-01-14 | 2021-03-30 | Nektar Therapeutics | Combination-based treatment method |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
TW202126293A (zh) | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
CN105712937B (zh) * | 2016-02-28 | 2019-02-22 | 河北宁格生物医药科技有限公司 | 一种治疗转移性肿瘤的化合物及其用途 |
WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
GB201709076D0 (en) * | 2017-06-07 | 2017-07-19 | Inst Of Cancer Research: Royal Cancer Hospital | Parp inhibitors for use in methods of treating cancer |
MA51524A (fr) * | 2018-01-05 | 2020-11-11 | Cybrexa 1 Inc | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques |
JP7372253B2 (ja) | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ(adp-リボース)ポリメラーゼ(parp)阻害剤との新規組合せ |
CN109232540A (zh) * | 2018-06-15 | 2019-01-18 | 深圳市坤健创新药物研究院 | 一种取代苯并咪唑衍生物及应用 |
CN108997320A (zh) * | 2018-08-30 | 2018-12-14 | 深圳市坤健创新药物研究院 | 一种含氟取代苯并咪唑衍生物及应用 |
CA3139180A1 (en) * | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
PE20220485A1 (es) | 2019-07-10 | 2022-04-04 | Cybrexa 3 Inc | Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos |
CN114053415A (zh) * | 2020-07-30 | 2022-02-18 | 江苏天士力帝益药业有限公司 | Tsl-1502复方药物组合 |
WO2023208341A1 (en) | 2022-04-27 | 2023-11-02 | ITM Isotope Technologies Munich SE | Combination treatment of small-cell lung cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100447539B1 (ko) * | 1995-08-02 | 2004-11-10 | 뉴캐슬 유니버시티 벤처스 리미티드 | 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법 |
WO1997007804A1 (en) * | 1995-08-28 | 1997-03-06 | Schering Corporation | Combination therapy for advanced cancer comprising temozolomide and cisplatin |
EP0932645A4 (en) * | 1997-07-02 | 2000-09-13 | Atochem North America Elf | FLUOROPOLYMERIC DISPERSION COATINGS MADE FROM VINYLIDENE POLYFLUORIDE RESINS |
SK285529B6 (sk) * | 1998-11-27 | 2007-03-01 | Basf Aktiengesellschaft | Substituované benzimidazoly, farmaceutická kompozícia s ich obsahom a ich použitie ako inhibítorov PARP |
NZ512731A (en) * | 1999-01-11 | 2004-01-30 | Agouron Pharma | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
ES2251987T3 (es) * | 1999-03-30 | 2006-05-16 | Schering Corporation | Tratamiento mejorado del cancer con temozolomida. |
DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
DE60335359D1 (de) * | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
BRPI0408996A (pt) * | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
ES2396334T3 (es) * | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
BRPI0517976A (pt) * | 2004-11-09 | 2008-10-21 | Schering Corp | métodos de tratamento |
TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
WO2006137510A1 (ja) * | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
-
2007
- 2007-01-17 JP JP2008551343A patent/JP5289060B2/ja not_active Expired - Fee Related
- 2007-01-17 DK DK11157696.3T patent/DK2338487T3/da active
- 2007-01-17 ES ES11157696.3T patent/ES2437132T3/es active Active
- 2007-01-17 CN CN2007800024112A patent/CN101370497B/zh not_active Expired - Fee Related
- 2007-01-17 PL PL11157696T patent/PL2338487T3/pl unknown
- 2007-01-17 SI SI200731329T patent/SI2338487T1/sl unknown
- 2007-01-17 CA CA2635691A patent/CA2635691C/en not_active Expired - Fee Related
- 2007-01-17 EP EP11157696.3A patent/EP2338487B1/en active Active
- 2007-01-17 ME MEP-2013-546A patent/ME02121B/me unknown
- 2007-01-17 WO PCT/US2007/001189 patent/WO2007084532A2/en active Application Filing
- 2007-01-17 EP EP11157682A patent/EP2329818A1/en not_active Withdrawn
- 2007-01-17 RS RS20130546A patent/RS53082B/en unknown
- 2007-01-17 EP EP07716699A patent/EP1976515A2/en not_active Withdrawn
- 2007-01-17 US US11/623,996 patent/US20070265324A1/en not_active Abandoned
- 2007-01-17 PT PT111576963T patent/PT2338487E/pt unknown
-
2011
- 2011-03-01 US US13/037,691 patent/US20110151023A1/en not_active Abandoned
- 2011-03-01 US US13/037,712 patent/US20110152336A1/en not_active Abandoned
- 2011-11-03 US US13/288,165 patent/US20120045524A1/en not_active Abandoned
-
2013
- 2013-02-12 JP JP2013024289A patent/JP2013136605A/ja not_active Withdrawn
- 2013-12-11 HR HRP20131180TT patent/HRP20131180T1/hr unknown
-
2015
- 2015-05-07 JP JP2015095009A patent/JP6147799B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-07 JP JP2017076489A patent/JP2017160216A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2338487A1 (en) | 2011-06-29 |
US20110152336A1 (en) | 2011-06-23 |
CN101370497B (zh) | 2010-11-17 |
CN101370497A (zh) | 2009-02-18 |
ES2437132T3 (es) | 2014-01-09 |
JP2017160216A (ja) | 2017-09-14 |
ME02121B (me) | 2014-06-30 |
EP1976515A2 (en) | 2008-10-08 |
US20070265324A1 (en) | 2007-11-15 |
EP2338487B1 (en) | 2013-09-11 |
CA2635691A1 (en) | 2007-07-26 |
DK2338487T3 (da) | 2013-12-09 |
US20120045524A1 (en) | 2012-02-23 |
WO2007084532A2 (en) | 2007-07-26 |
WO2007084532A3 (en) | 2007-09-07 |
HRP20131180T1 (hr) | 2014-01-31 |
US20110151023A1 (en) | 2011-06-23 |
PT2338487E (pt) | 2013-12-16 |
JP2009523801A (ja) | 2009-06-25 |
RS53082B (en) | 2014-06-30 |
JP2013136605A (ja) | 2013-07-11 |
JP5289060B2 (ja) | 2013-09-11 |
CA2635691C (en) | 2013-10-29 |
JP6147799B2 (ja) | 2017-06-14 |
JP2015187114A (ja) | 2015-10-29 |
PL2338487T3 (pl) | 2014-03-31 |
EP2329818A1 (en) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME02121B (me) | Kombinovana terapija sa parp inhibitorima | |
IL196559A0 (en) | Combination therapy | |
GB0609492D0 (en) | Therapeutic agents | |
GB0608928D0 (en) | Therapeutic agents | |
ZA200904860B (en) | Combination therapy with angiogenesis inhibitors | |
GB2436010B (en) | Therapy device | |
GB0601962D0 (en) | Therapeutic agents | |
EP2035005A4 (en) | THERAPY BASED ON CYTOKINE INHIBITORS | |
EP2032168A4 (en) | COMBINED THERAPY BASED ON CAPECITABINE | |
EP2117311A4 (en) | THERAPEUTICS | |
IL196556A0 (en) | Combination therapy | |
GB0616214D0 (en) | Therapeutic Agents | |
IL199992A0 (en) | Combination therapy | |
EP2054061A4 (en) | COMBINATION THERAPY | |
GB0611152D0 (en) | Therapeutic agents | |
GB0620818D0 (en) | Therapeutic agents | |
IL198026A0 (en) | Sequential combination therapy | |
GB0620059D0 (en) | Therapeutic agents | |
ZA200902203B (en) | Combination therapy | |
GB0609676D0 (en) | Therapeutic agents | |
EP2211863A4 (en) | COMBINATION THERAPY | |
GB2441007B (en) | Auricular therapy | |
GB0700284D0 (en) | Combination therapy | |
GB0622195D0 (en) | Therapeutic agents | |
GB0606660D0 (en) | Targeted Therapy |